Nat Commun: New study lays the groundwork for targeted removal of leukemia stem cells

Leukemia is caused by leukemia stem cells, which are resistant to most known treatments.
recurrence is also due to this resistance.
leukemia stem cells come from normal hematopoietic stem cells.
because of their close relationship, leukemia stem cells and hematopoietic stem cells have many of the same signal transducting pathways.
if you want to stop the proliferation of leukemia stem cells, the key is to find signaling path paths that are active only in leukemia stem cells, not in normal hematopoietic stem cells.
to this goal, Professor Adrian Ochsenbein of the University of Bern in Switzerland and his team are working on the Department of Medical Oncology at Inselspital, a university hospital in Bern.
their newly discovered LIGHT/LTbR path, published on February 16, 2021 in the journal Nature Communications, under the title "LIGHT/LT beta Signaling Regulations self-renewal and derivation of hematopoietic and leuk stememia cells."
a new way to control leukemia stem cells, the LIGHT/LT betaR signaling path path is not effective in hematopoietic stem cells during normal blood formation.
only if demand increases, such as after chemotherapy, does it play an important role in maintaining stem cell function.
, leukemia stem cells always rely on this signaling path.
the LIGHT/LTbR signaling pathrapy leads to an increase in symmetrical cell division, leading to the proliferation of leukemia stem cells.
if the path of the path, such as monoclonal antibodies, were blocked, leukemia stem cells would lose stem cell function and die.
, the number of LIGHT binding points in leukemia stem cells was significantly higher than that of normal hematopoietic stem cells.
laboratory experiments, animals with leukemia survived significantly longer when the newly discovered signaling path was blocked.
latest contribution is the light of hope for future leukemia treatment The results of this study show that multiple subjects/couples maintain the participating leukemia stem cells.
the researchers believe the new method, blocking LIGHT, could improve treatment for various types of leukemia in the future.
drug treatment aimed at blocking various immune receptors and mating bodies has led to changes in cancer treatment.
, however, important drugs used to treat solid tumors are ineffective in treating leukemia.
, the CD70/CD27 and LIGHT/LT beta R signaling pathras identified by these researchers are important advances in improving immunotherapy for myeloid leukemia.
team at Stanford University in the United States has developed antibodies targeting CD47 to activate another immune signaling path (swallowing).
these new drugs have entered phase II development for the treatment of acute myeloid leukemia (AML).
: 1. Sabine Höpner et al. LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nature Communications, 2021, doi:10.1038/s41467-021-21317-x.2. Targeted out of leukemic stem cells This article was originally published from Bio Valley, please download Bio Valley APP for more information (